Increased expression of interleukin-6 by vasoactive intestinal peptide is associated with regulation of CREB, AP-1 and C/EBP, but not NF-κB, in mouse calvarial osteoblasts
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Impact of VIP and cAMP on the regulation of TNF-α and IL-10 production: implications for rheumatoid arthritisArthritis Research & Therapy, 2003
- cAMP Analog Mapping of Epac1 and cAMP KinaseJournal of Biological Chemistry, 2003
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microgliaJournal of Leukocyte Biology, 2003
- A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERKNature Cell Biology, 2002
- Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bonesBone, 2002
- Vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide inhibit chemokine production in activated microgliaGlia, 2002
- Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) as Modulators of Both Innate and Adaptive ImmunityCritical Reviews in Oral Biology & Medicine, 2002
- Inhibition of Endotoxin-Induced Macrophage Chemokine Production by Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide In Vitro and In VivoThe Journal of Immunology, 2001
- Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the diseaseNature Medicine, 2001
- Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit Expression of Fas Ligand in Activated T Lymphocytes by Regulating c-Myc, NF-κB, NF-AT, and Early Growth Factors 2/3The Journal of Immunology, 2001